Amelioration of Glycemic Control by Sleeve Gastrectomy and Gastric Bypass in a Lean Animal Model of Type 2 Diabetes: Restoration of Gut Hormone Profile

Obesity Surgery

Volumn 25, Issue 1, 2015, Pages 7-18

  Eickhoff, Hans ^a,b   Louro, Teresa M ^b,c   Matafome, Paulo N ^b,c   Vasconcelos, Filipa ^b   Seiça, Raquel M ^b,c   Castro e Sousa, Francisco ^b,d  

^a Hospital de Santiago   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Diabetes surgery; Gastric bypass; Ghrelin; GLP 1; Goto Kakizaki rats; Metabolic surgery; PYY; Sleeve Gastrectomy

Indexed keywords

GLUCOSE BLOOD LEVEL; INSULIN;

ANIMAL; BLOOD; BODY WEIGHT; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GASTRECTOMY; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RAT; STOMACH BYPASS; TREATMENT OUTCOME; WEIGHT REDUCTION; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GASTRECTOMY; GASTRIC BYPASS; HUMANS; INSULIN; MALE; RATS; RATS, WISTAR; THINNESS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84939893973     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-014-1309-8     Document Type: Article

References (60)

1. WHO. WHO | Diabetes. Factsheet no. 312. World Health Organization; 2012;
2. Unick JL, Beavers D, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, et al. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care. 2011;34:2152–7.
3. Sjöström L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.
4. Sjöström L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes (Lond). 2008;32 Suppl 7:S93–7.
5. Pories WJ, Caro JF, Flickinger EG, Meelheim HD, Swanson MS. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville gastric bypass. Ann Surg. 1987;206:316–23.
6. Pories WJ, MacDonald K, Morgan EJ, Sinha MK, Dohm GL, Swanson MS, et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr Am Soc Nutr. 1992;55:582S–5S.
7. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.
8. Smith S, Edwards C, Goodman G. Changes in diabetic management after Roux-en-Y gastric bypass. Obes Surg. 1996;6:345–8.
9. Scopinaro N, Adami GF, Marinari GM, Gianetta E, Traverso E, Friedman D, et al. Biliopancreatic diversion. World J Surg. 1998;22:936–46.
10. Marinari GM, Papadia FS, Briatore L, Adami G, Scopinaro N. Type 2 diabetes and weight loss following biliopancreatic diversion for obesity. Obes Surg. 2006;16:1440–4.
11. Scopinaro N, Adami GF, Papadia FS, Camerini G, Carlini F, Briatore L, et al. The effects of biliopancreatic diversion on type 2 diabetes mellitus in patients with mild obesity (BMI 30-35 kg/m2) and simple overweight (BMI 25-30 kg/m2): a prospective controlled study. Obes Surg. 2011;21:880–8.
12. Pontiroli AE, Pizzocri P, Librenti MC, Vedani P, Marchi M, Cucchi E, et al. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab. 2002;87:3555–61.
13. Silecchia G, Boru C, Pecchia A, Rizzello M, Casella G, Leonetti F, et al. Effectiveness of laparoscopic sleeve gastrectomy (first stage of biliopancreatic diversion with duodenal switch) on co-morbidities in super-obese high-risk patients. Obes Surg. 2006;16:1138–44.
14. Nocca D, Guillaume F, Noel P, Picot MC, Aggarwal R, El Kamel M, et al. Impact of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on HbA1c blood level and pharmacological treatment of type 2 diabetes mellitus in severe or morbidly obese patients. Results of a multicenter prospective study at 1 year. Obes Surg. 2011;21:738–43.
15. De Gordejuela AGR, Pujol Gebelli J, García NVNV, Alsina EFF, Medayo LS, Masdevall Noguera C. Is sleeve gastrectomy as effective as gastric bypass for remission of type 2 diabetes in morbidly obese patients? Surg Obes Relat Dis Elsevier Inc. 2011;7:506–9.
16. Cutolo PP, Nosso G, Vitolo G, Brancato V, Capaldo B, Angrisani L. Clinical efficacy of laparoscopic sleeve gastrectomy vs laparoscopic gastric bypass in obese type 2 diabetic patients: a retrospective comparison. Obes Surg. 2012;22:1535–9.
17. Abbatini F, Capoccia D, Casella G, Coccia F, Leonetti F, Basso N. Type 2 diabetes in obese patients with body mass index of 30-35 kg/m2: sleeve gastrectomy versus medical treatment. Surg Obes Relat Dis Elsevier Inc. 2012;8:20–4.
18. Boza C, Muñoz R, Salinas J, Gamboa C, Klaassen J, Escalona A, et al. Safety and efficacy of Roux-en-Y gastric bypass to treat type 2 diabetes mellitus in non-severely obese patients. Obes Surg. 2011;21:1330–6.
19. Lanzarini E, Csendes A, Gutierrez L, Cuevas P, Lembach H, Molina JC, et al. Type 2 diabetes mellitus in patients with mild obesity: preliminary results of surgical treatment. Obes Surg. 2013;23:234–40.
20. Samols E, Marri G, Marks V. Promotion of insulin secretion by glucagon. Lancet. 1965;2:415–6.
21. Samols E, Tyler J, Marri G, Marks V. Stimulation of glucagon secretion by oral glucose. Lancet. 1965;2:1257–9.
22. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987;79:616–9.
23. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2:1300–4.
24. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276:R1541–4.
25. Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Juul Holst J. Astrup a. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety—effect of obesity and weight reduction. Int J Obes Relat Metab Disord. 2001;25:1206–14.
26. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJB. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006;93:210–5.
27. Le Roux CW, Aylwin SJB, Batterham RL, Borg CM, Coyle F, Prasad V, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108–14.
28. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.
29. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–30.
30. Leonetti F, Silecchia G, Iacobellis G, Ribaudo MC, Zappaterreno A, Tiberti C, et al. Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab. 2003;88:4227–31.
31. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908–13.
32. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992–5.
33. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86:5083–6.
34. Tatemoto K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci U S A. 1982;79:2514–8.
35. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418:650–4.
36. Seiça RM, Martins MJ, Pessa PB, Santos RM, Rosário LM. do, Suzuki KI, et al. Morphological changes of islet of Langerhans in an animal model of type 2 diabetes. Acta Med Port. 2003;16:381–8.
37. Portha B, Lacraz G, Kergoat M, Homo-Delarche F, Giroix M-H, Bailbé D, et al. The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes? Mol Cell Endocrinol. 2009;297:73–85.
38. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1–11.
39. Pacheco D, de Luis DA, Romero A, González Sagrado M, Conde R, Izaola O, et al. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg. 2007;194:221–4.
40. Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9.
41. Patriti A, Aisa MC, Annetti C, Sidoni A, Galli F, Ferri I, et al. How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-Kakizaki rats through an enhanced Proglucagon gene expression and L-cell number. Surgery. 2007;142:74–85.
42. De Bona Castelan J, Bettiol J, D'Acampora AJ, Castelan JVE, de Souza JC, Bressiani V, et al. Sleeve gastrectomy model in Wistar rats. Obes Surg. 2007;17:957–61.
43. Meguid MM, Ramos EJB, Suzuki S, Xu Y, George ZM, Das UN, et al. A surgical rat model of human Roux-en-Y gastric bypass. J Gastrointest Surg. 2004;8:621–30.
44. Liu Y, Zhou Y, Wang Y, Geng D, Liu J. Roux-en-Y gastric bypass-induced improvement of glucose tolerance and insulin resistance in type 2 diabetic rats are mediated by glucagon-like peptide-1. Obes Surg. 2011;21:1424–31.
45. Donglei Z, Liesheng L, Xun J, Chenzhu Z, Weixing D. Effects and mechanism of duodenal-jejunal bypass and sleeve gastrectomy on GLUT2 and glucokinase in diabetic Goto-Kakizaki rats. Eur J Med Res. 2012;17:15.
46. De Luis D, Domingo M, Romero A, Gonzalez Sagrado M, Pacheco D, Primo D, et al. Effects of duodenal-jejunal exclusion on beta cell function and hormonal regulation in Goto-Kakizaki rats. Am J Surg Elsevier Inc. 2012;204:242–7.
47. Kindel TL, Yoder SM, Seeley RJ, D’Alessio DA, Tso P. Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. J Gastrointest Surg. 2009;13:1762–72.
48. Frühbeck G, Rotellar F, Hernández-Lizoain JL, Gil MJ, Gómez-Ambrosi J, Salvador J, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg. 2004;14:1208–15.
49. Faraj M, Havel PJ, Phélis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88:1594–602.
50. Holdstock C, Engström BE, Ohrvall M, Lind L, Sundbom M, Karlsson FA. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab. 2003;88:3177–83.
51. Sun D, Liu S, Zhang G, Chen W, Yan Z, Hu S. Type 2 Diabetes Control in a nonobese rat model using sleeve gastrectomy with duodenal-jejunal bypass (SGDJB). Obes Surg. 2012;22:1865–73.
52. Trung VN, Yamamoto H, Yamaguchi T, Murata S, Akabori H, Ugi S, et al. Effect of sleeve gastrectomy on body weight, food intake, glucose tolerance, and metabolic hormone level in two different rat models: Goto-Kakizaki and diet-induced obese rat. J Surg Res Elsevier Ltd. 2013;185:159–65.
53. Shin AC, Zheng H, Townsend RL, Sigalet DL, Berthoud H-R. Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology. 2010;151:1588–97.
54. Cummings BP, Strader AD, Stanhope KL, Graham JL, Lee J, Raybould HE, et al. Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology. 2010;138:2437–46. 2446.e1.
55. DePaula AL, Macedo ALV, Schraibman V, Mota BR, Vencio S, Ludovico A, et al. Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34. Surg Endosc. 2009;23:1724–32.
56. Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22:740–8.
57. Tsoli M, Chronaiou A, Kehagias I, Kalfarentzos F, Alexandrides TK. Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study. Surg Obes Relat Dis. 2013;9:667–77.
58. Beglinger S, Drewe J, Schirra J, Göke B, D’Amato M, Beglinger C. Role of fat hydrolysis in regulating glucagon-like peptide-1 secretion. J Clin Endocrinol Metab. 2010;95:879–86.
59. Shrestha YB, Wickwire K, Giraudo SQ. Direct effects of nutrients, acetylcholine, CCK, and insulin on ghrelin release from the isolated stomachs of rats. Peptides. 2009;30:1187–91.
60. Broglio F, Gottero C, Van Koetsveld P, Prodam F, Destefanis S, Benso A, et al. Acetylcholine regulates ghrelin secretion in humans. J Clin Endocrinol Metab. 2004;89:2429–33.